Subjective Experience Following Psilocybin
Condition(s) studied
Investigational drug(s) / intervention(s)
Psilocybin high-dose: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose
Psilocybin low-dose: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose.
Risperidone 1 MG: risperidone 1mg capsules
Placebo: inactive placebo
Study summary
The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with either a placebo or risperidone, an atypical antipsychotic that block the subjective effects of psilocybin.
Eligibility
Primary outcome measure(s)
- Positive effects — One week and one month post-dosing
Persisting Effects Questionnaire (PEQ) - 145 questions rated using a 6-point Likert scale from 0 to 6. There are 12 sub-scale themes assessing positive and negative changes in Attitudes About Life, Attitudes About Self, Mood Changes, Social Effects, Behavioural Changes, and Spirituality. Higher scores in the positive sub-scales indicate a better outcome, while higher scores in the negative sub-scales indicate a worse outcome.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Calgary | Calgary | Alberta | Recruiting |
More University of Calgary trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06768944 on ClinicalTrials.gov ↗ ← All trials in Canada